Skip to main content
    N

    Nuvation Bio Inc (NUVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $3.86
    -0.13 (-3.26%)

    Market Cap: $1.41B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nuvation Bio Inc (NUVB) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Nuvation Bio (NUVB) to earn -$0.29 per share in the fiscal year ending Dec 31, 2026, on revenue of $203.17M. Of 13 analysts, 12 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.85, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.

    RatingAnalystsShare
    Strong Buy323.1%
    Buy969.2%
    Hold17.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 23.5%.

    Fiscal year ending Dec 31, 2026
    -$0.29
    EPS consensus, revenue $203.17M
    Fiscal year ending Dec 31, 2027
    -$0.08
    EPS consensus, revenue $250.89M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.29-$0.30 to -$0.282$203.17M$190.60M to $236.43M13
    Dec 31, 2027-$0.08-$0.16 to $0.002$250.89M$199.10M to $332.43M13

    Quarterly Estimates

    The EPS consensus rises from -$0.11 for the quarter ending Dec 31, 2026 to -$0.06 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.11-$0.14 to -$0.0315$45.16M$32.24M to $79.80M15
    Mar 31, 2027-$0.06-$0.12 to $0.004$56.73M$36.60M to $80.00M4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202701
    Quarter ending Mar 31, 202701

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.29-$0.29-$0.29-$0.29-$0.29N/A
    Fiscal year ending Dec 31, 2027-$0.08-$0.02-$0.02-$0.02-$0.02N/A
    Quarter ending Mar 31, 2027-$0.06-$0.03-$0.04-$0.03-$0.03N/A

    Frequently Asked Questions About NUVB

    What is the NUVB stock forecast?

    Consensus analyst estimates put Nuvation Bio's EPS at -$0.29 for the fiscal year ending Dec 31, 2026, on revenue of $203.17M. The consensus rating from 13 analysts is Buy.

    How do analysts rate NUVB stock?

    Of 13 analysts covering Nuvation Bio, 3 rate it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from NUVB next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.29, with estimates from -$0.30 to -$0.28 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.08, with estimates from -$0.16 to $0.00 from 2 analysts.

    What revenue do analysts expect from Nuvation Bio next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $203.17M, with estimates from $190.60M to $236.43M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $250.89M, with estimates from $199.10M to $332.43M.

    How many analysts cover NUVB?

    13 analysts rate Nuvation Bio stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.